Cubist gets option to acquire pain management biotech Adynxx; option not exercised
In exchange for a $20mm up-front fee, acute care product company Cubist Pharmaceuticals Inc. has obtained the exclusive option to buy closely held Adynxx Inc. (pain management) following receipt of the Phase II data on Adynxx’s lead pain drug AYX1 (the proof-of-concept trial enrolled its first patient concurrent with this announcement). Should Cubist exercise the option, it would pay $40mm plus development, regulatory, and sales earn-outs.
- Antisense, Oligonucleotides
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.